CANF · Can-Fite Biopharma Ltd ADR
United States · RS rating 8 · As of 2026-11-03
| Price | 1.62 USD |
|---|---|
| 1-day change | -0.6% |
| RS rating (overall / 1M / 3M / 12M) | 8 / 17 / 9 / 9 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 16 / 7 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +80.7% |
| Market cap (USD) | $6.2M |